NPS RADAR December 2007NPS RADAR December 2007

NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.

Find out more about NPS RADAR.



Title Why read this
NPS RADAR December 2007 Professional publication - NPS RADAR - Complete issue NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.
Quetiapine (Seroquel) PBS listed for acute mania Professional publication - NPS RADAR - Brief item PBS listing of quetiapine (Seroquel) was extended to include acute mania associated with bipolar disorder, with streamlined authority allowing an episode of acute mania to be treated for up to 6 months.
Sevelamer (Renagel) 800 mg tablets PBS listed for adults with chronic kidney disease who are on dialysis Professional publication - NPS RADAR - Brief item Sevelamer (Renagel) was listed on the PBS for the treatment of hyperphosphataemia in adults with chronic kidney disease who are on dialysis.
Another ultra-short-acting insulin PBS listed: insulin glulisine Professional publication - NPS RADAR - Brief item Insulin glulisine (Apidra) is the third ultra-short-acting insulin analogue listed on the PBS, the others being insulin lispro and insulin aspart, for treatment of type 1 and type 2 diabetes.
Topiramate (Topamax) for migraine prevention Professional publication - NPS RADAR - Review Review of topiramate (Topamax) for migraine prevention as second-line agent, with emphasis on non-drug therapies and safety issues.

Complete list of all NPS RADAR content.

Find out more about NPS RADAR.

Date published: 2007-12-01 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.